Increases sexual desire and function for men and women.
- Minimal or no undesirable side effects.
- Decrease body fat mass and reduce food intake.
- Induces skin tanning at low doses.
- Potent self-tanner applications.
FOR A DETAILED ANALYSIS PLEASE SEE THE BELOW ARTICE AND VIEW
THE REFERENCED SOURCES:
Melanotan II also known as PT-141 was developed by researchers
at the University of Arizona College of Medicine. Melanotan II
is an analog of the peptide hormone alpha-melanocyte stimulating
hormone (?-MSH), this hormone provides a therapeutic tan with
the ability to lower the risk of skin cancer, (MSH) also plays
an important role in regulating sexual arousal in men and women.
Melanotan II has the additional effect of decreasing body fat
mass. Melanotan II It is a cyclic lactyam analog of alpha-MSH
with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2.
Melanotan II is in a class of peptide hormone known as Melanocortins
(MCs). Melanocortins (MCs) are multifunctional peptide hormones
that regulate a diversity of physiological functions. MCs have
been implicated in sexual function in animals.
A MC analog, Melanotan II (MTII), can enhance sexual function
in human males (erectile activity) and females (increased levels
of sexual desire and genital arousal). Unlike other sexual-enhancement
drugs, MTII works at the level of the brain, thus eliciting a
rather natural sexual response with minimal or no undesirable
side effects. The actions of the peptide were discovered accidentally
while studying the effects of the peptide and related analogs
on human skin pigmentation (tanning). Hadley ME (2005).
Melanotan II, PT-141, a cyclic heptapeptide melanocortin analog,
was evaluated following subcutaneous administration to healthy
male subjects and to patients with erectile dysfunction (ED) who
report an inadequate response to Viagra. The erectile response
induced by PT-141 was statistically significant at both doses.
PT-141 was safe and well tolerated in both studies. The erectogenic
potential of PT-141, its tolerability profile and its ability
to cause significant erections in patients who do not have an
adequate response to a PDE5 inhibitor suggest that PT-141 may
provide an alternative treatment for ED with a potentially broad
patient base.Rosen RC, Diamond LE, Earle DC, Shadiack AM,Molinoff
PB (2004).
In addition to the sexual enhancement and tanning effects of
Melanotan II, MT-II has also exhibited the potential to decrease
body fat mass and reduce food intake. Choi YH, Li C, Hartzell
DL, Lin J, Della-Fera MA, Baile CA (2003).
MT-II has tanning activity in humans given only 5 low doses every
other day by subcutaneous injection. The recommended single MT-II
dose for future Phase I studies is 0.025 mg/kg/day.
